Recently, Amarin presented REDUCE-IT results at AHA. Although there has been a large volume of news and interpretation on the potential for REDUCE-IT to be practice-changing in preventive cardiology, there has been even more talk about Amarin as the hottest take-out target in the industry, despite the growing short interest post-results. In this original research report, FENIX provides a winners-losers-and-suitors analysis, including the rationale and context for why Amarin could be bought by top suitors before REDUCE-IT’s FDA approval, why popular choice suitors would NOT be interested, how the current regulatory environment works in Amarin’s favor, and what an updated Vascepa label could look like. This report is the advanced read that separates itself from all the other REDUCE-IT trial-related analyses you’ve already seen, covering the Amarin market opportunity from the perspectives of Amgen, Sanofi, Novartis, Merck, Lilly, BI, Janssen, Novo Nordisk, Pfizer, Gilead, Esperion, and The Medicines Company.
An inside advanced look at the section titles
In this original research report by FENIX, the following section titles provide a glimpse of the authors’ deep cardiometabolic expertise and analysis:
- The top Amarin suitors
- Popular choices that don’t quite fit
- Loser: AstraZeneca
- Esperion and The Medicines Company could be affected
- What about…
- Dark horses
- Other relevant thoughts
- The US regulatory environment is highly favorable to reward innovation in cardiometabolic disease
Take action now knowing the full scope of the opportunity and the implications it has on the market.
This content is for Read Less members only.
Register
